Case study: contamination of heparin with oversulfated chondroitin sulfate
Review published in Handbook of experimental pharmacology (2012)
Abstract
In late 2007 and early 2008, a cluster of adverse events in patients receiving Heparin Sodium Injection occurred in the United States and in some countries in Europe. The adverse events were reported as being "allergic type" reactions, chiefly characterized by acute hypotension, nausea, and shortness of breath. The root cause of the cluster of adverse events was determined to be a contamination of the heparin by oversulfated chondroitin sulfate. The isolation and structure determination of this contaminant was accomplished by an FDA-led consortium of academic and government laboratories and independently by Baxter Healthcare, whose vial products were first identified in the USA as being associated with the adverse events. Oversulfated chondroitin sulfate was shown to produce acute hypotension in animal models, demonstrating that it was most likely the causative agent responsible for certain of the reported adverse events in patients receiving the contaminated heparin products.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
This case study recounts how an FDA-led consortium and Baxter Healthcare identified oversulfated chondroitin sulfate as the root cause of the 2007-2008 "allergic-type" heparin reactions; the contaminant produced acute hypotension in animal models.
Context
This article reviews the 2007-2008 heparin contamination crisis, describing how an FDA-led consortium and Baxter Healthcare isolated and identified oversulfated chondroitin sulfate as the root cause of allergic-type adverse events including acute hypotension, nausea, and shortness of breath. The contaminant was shown to produce acute hypotension in animal models, supporting it as the causative agent. The work underscores the importance of safety and purity in biological therapeutics. However, the abstract makes no mention of leeches, hirudotherapy, hirudin, or leech secretions.
Citation
Reference (Vancouver style)
Chess EK, Bairstow S, Donovan S, Havel K, Hu P, Johnson RJ, et al. Case study: contamination of heparin with oversulfated chondroitin sulfate. Handb Exp Pharmacol. 2012;(207):99-125. doi:10.1007/978-3-642-23056-1_6. PMID: 22566223
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026